

Financial news for BLUE dated on 2020-06-07: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage

Financial news for BLUE dated on 2020-05-28: Morgan Stanley Maintains Equal-Weight on bluebird bio, Raises Price Target to \$73

Financial news for BLUE dated on 2020-05-28: SVB Leerink Maintains Outperform on bluebird bio, Raises Price Target to \$129

Financial news for BLUE dated on 2020-05-27: Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold \$15B In Peak Sales Potential

Financial news for BLUE dated on 2020-05-20: Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.

Financial news for BLUE dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for BLUE dated on 2020-05-18: Bluebird Bio shares are trading lower after the company announced a \$400 million common stock offering.

Financial news for BLUE dated on 2020-05-18: Bluebird Bio Announces \$400M Common Stock Offering

Financial news for BLUE dated on 2020-05-14: bluebird bio To Present Data From Gene, Cell Therapy Programs At European Hematology Association Annual Congress On Jun. 12

Financial news for BLUE dated on 2020-05-13: Bristol Myers, bluebird bio Will Present Updated Results From Pivotal KarMMA Study Of Ide-cel In Relapsed and Refractory Multiple Myeloma Patients at ASCO On May 29

Financial news for BLUE dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for BLUE dated on 2020-05-13: 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLUE dated on 2020-05-13: Bluebird Bio shares are trading lower after the company announced upon its preliminary review, the FDA determined that the chemistry, manufacturing and control module of the BLA for Idecabtagene Vicleucel requires further detail to complete the review.

Financial news for BLUE dated on 2020-05-13: Bristol Myers Squibb And bluebird bio Say Upon Preliminary Review, FDA Determined That The Chemistry, Manufacturing And Control Module Of The BLA For Idecabtagene Vicleucel Requires Further Detail To Complete The Review

Financial news for BLUE dated on 2020-05-13: RBC Capital Initiates Coverage On bluebird bio with Outperform Rating, Announces Price Target of \$100

Financial news for BLUE dated on 2020-05-12: BMO Capital Maintains Outperform on bluebird bio, Raises Price Target to \$112

Financial news for BLUE dated on 2020-05-11: Bluebird Bio shares are trading higher after the company reported better-than-expected Q1 EPS results. The company also announced it amended its existing co-development agreement with Bristol Myers Squibb. Bristol Myers Squibb will buy out its obligation to pay future ex-U.S. milestones and royalty payments for \$200 million.

Financial news for BLUE dated on 2020-05-11: Bluebird Bio Announces Amended BCMA CAR-T Collaboration Agreement; Bristol Myers Squibb To Buy Out Its Ex-US Milestone And Royalty Obligations To Bluebird Bio For \$200 Million

Financial news for BLUE dated on 2020-05-11: Hitachi Chemical Advanced Therapeutics Solutions And Apiceth Biopharma Enter Into Strategic Clinical And Commercial Manufacturing Agreements With Bluebird Bio

Financial news for BLUE dated on 2020-05-11: bluebird bio Q1 EPS \$(3.640) Beats \$(4.010) Estimate

Financial news for BLUE dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for BLUE dated on 2020-05-08: bluebird bio Reports Updated Results From Pivotal Phase 2 KarMMA Study At ASCO 2020 Virtual Program

Financial news for BLUE dated on 2020-05-07: Shares of several healthcare companies

are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.

Financial news for BLUE dated on 2020-05-01: Shares of several healthcare companies are trading lower on market weakness as investor uncertainty grows following quarterly earnings results from multiple companies.

Financial news for BLUE dated on 2020-04-15: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$69

Financial news for BLUE dated on 2020-04-09: Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further \$2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.

Financial news for BLUE dated on 2020-03-31: Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application For Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel To FDA

Financial news for BLUE dated on 2020-03-27: Stifel Upgrades bluebird bio to Buy, Lowers Price Target to \$70

Financial news for BLUE dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for BLUE dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for BLUE dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for BLUE dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for BLUE dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for BLUE dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for BLUE dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for BLUE dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for BLUE dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for BLUE dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for BLUE dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for BLUE dated on 2020-02-26: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$92

Financial news for BLUE dated on 2020-02-20: 78 Biggest Movers From Yesterday

Financial news for BLUE dated on 2020-02-19: Raymond James Downgrades Bluebird Bio From Strong Buy To Market Perform

Financial news for BLUE dated on 2020-02-19: 51 Stocks Moving In Wednesday's Mid-Day Session

Financial news for BLUE dated on 2020-02-19: Bluebird Bio shares are trading lower after the company reported Q4 EPS and sales results down from last year.

Financial news for BLUE dated on 2020-02-19: Stifel Nicolaus Maintains Hold on bluebird bio, Lowers Price Target to \$94

Financial news for BLUE dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for BLUE dated on 2020-02-18: bluebird bio Q4 EPS \$(4.04) Down From \$(2.72) YoY, Sales \$9.997M Down From \$19.243M YoY

Financial news for BLUE dated on 2020-02-18: bluebird bio Q4 Sales \$9.997M Down From \$19.243M YoY

Financial news for BLUE dated on 2020-02-04: 85 Biggest Movers From Yesterday

Financial news for BLUE dated on 2020-02-03: 61 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2020-02-03: Benzinga's Top Upgrades, Downgrades For February 3, 2020

Financial news for BLUE dated on 2020-02-03: Bluebird Bio shares are trading higher after Evercore ISI upgraded the stock from In-Line to Outperform and raised the price target from \$86 to \$100.

Financial news for BLUE dated on 2020-02-03: 10 Biggest Price Target Changes For Monday

Financial news for BLUE dated on 2020-02-03: Evercore ISI Group Upgrades bluebird bio to Outperform, Raises Price Target to \$100

Financial news for BLUE dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for BLUE dated on 2020-01-14: Bluebird Bio shares are trading higher after the company announced the launch of ZYNTEGLO gene therapy in Germany for patients with transfusion-dependent b-thalassemia who do not have b0/b0 genotype.

Financial news for BLUE dated on 2020-01-13: bluebird bio Announces Launch in Germany of ZYNTEGLO Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent b-Thalassemia Who Do Not Have b0/b0 Genotype

Financial news for BLUE dated on 2019-12-26: Bluebird Bio shares are trading lower. Not seeing any news to justify the price action.

Financial news for BLUE dated on 2019-12-13: Bluebird Bio shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a price target of \$135 per share.

Financial news for BLUE dated on 2019-12-13: Oppenheimer Upgrades bluebird bio to Outperform, Announces \$135 Price Target

Financial news for BLUE dated on 2019-12-11: 66 Biggest Movers From Yesterday

Financial news for BLUE dated on 2019-12-10: Bluebird Bio shares are trading higher on updated results from its Phase 1 trial evaluating its CAR-T candidate bb21217.

Financial news for BLUE dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for BLUE dated on 2019-12-09: bluebird bio Highlights Presentation Of New Data Demonstrating Long-Term Transfusion Independence And Safety For LentiGlobin Gene Therapy For b-thalassemia At 61st ASH Annual Meeting And Exposition

Financial news for BLUE dated on 2019-12-09: Wells Fargo Maintains Overweight on bluebird bio, Lowers Price Target to \$160

Financial news for BLUE dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2019-12-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2019-12-07: bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin Gene Therapy for Sickle Cell Disease at ASH 2019

Financial news for BLUE dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for BLUE dated on 2019-12-06: Bristol-Myers, bluebird bio Report Top-Line Results From Phase 2 KarMMa Study Of Ide-cel: Met Primary, Key Secondary Endpoints

Financial news for BLUE dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for BLUE dated on 2019-11-26: UPDATE: SVB Leerink Upgrades bluebird

bio to Outperform, Reiterates \$119 Target Notes Co. 'is trading just below our zero B-cell maturation antigen (BCMA) value estimate of \$77/share - setting up an attractive risk/reward into BCMA data'

Financial news for BLUE dated on 2019-11-26: Benzinga's Top Upgrades, Downgrades For November 26, 2019

Financial news for BLUE dated on 2019-11-26: Bluebird Bio shares are trading higher after SVB Leerink upgraded the stock from Market Perform to Outperform and announced a price target of \$119 per share.

Financial news for BLUE dated on 2019-11-26: SVB Leerink Upgrades bluebird bio to Outperform, Announces \$119 Price Target

Financial news for BLUE dated on 2019-11-19: Benzinga's Top Upgrades, Downgrades For November 19, 2019

Financial news for BLUE dated on 2019-11-19: Evercore ISI Group Downgrades bluebird bio to In-Line, Announces \$86 Price Target

Financial news for BLUE dated on 2019-11-12: Bluebird Bio And Forty Seven Announce A Research Collaboration To Study An All Antibody Conditioning Regimen For Use In Combination With Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

Financial news for BLUE dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for BLUE dated on 2019-11-11: Stocks That Hit 52-Week Lows On Monday

Financial news for BLUE dated on 2019-11-08: Stocks That Hit 52-Week Lows On Friday

Financial news for BLUE dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for BLUE dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for BLUE dated on 2019-11-04: Benzinga's Top Upgrades, Downgrades For November 4, 2019

Financial news for BLUE dated on 2019-11-04: Wedbush Upgrades bluebird bio to Outperform

Financial news for BLUE dated on 2019-11-01: Piper Jaffray Maintains Neutral on bluebird bio, Lowers Price Target to \$85

Financial news for BLUE dated on 2019-11-01: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$100

Financial news for BLUE dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for BLUE dated on 2019-10-31: Bluebird Bio shares are trading lower after the company reported Q3 EPS and sales results down from last year.

Financial news for BLUE dated on 2019-10-31: bluebird bio Q3 EPS \$(3.73) Down From \$(2.73) YoY, Sales \$8.91M Down From \$11.528M YoY

Financial news for BLUE dated on 2019-10-25: Stocks That Hit 52-Week Lows On Friday

Financial news for BLUE dated on 2019-10-25: The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

Financial news for BLUE dated on 2019-10-24: Stocks That Hit 52-Week Lows On Thursday

Financial news for BLUE dated on 2019-10-22: European Medicines Agency Approves Refined Commercial Manufacturing Specifications For ZYNTEGLO

Financial news for BLUE dated on 2019-10-11: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$104

Financial news for BLUE dated on 2019-10-04: The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering

Financial news for BLUE dated on 2019-10-03: Stocks That Hit 52-Week Lows On Thursday

Financial news for BLUE dated on 2019-10-03: The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo

Financial news for BLUE dated on 2019-10-02: Stocks That Hit 52-Week Lows On Wednesday

Financial news for BLUE dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for BLUE dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for BLUE dated on 2019-10-01: Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio

Financial news for BLUE dated on 2019-10-01: UPDATE: Stifel Initiates bluebird bio With Hold, \$109 Target As Firm Thinks 'the launch of their lead product Zynteglo will be slow, and there's risk this could lag consensus expectations (informed by a payer survey)'

Financial news for BLUE dated on 2019-10-01: Benzinga's Top Upgrades, Downgrades For October 1, 2019

Financial news for BLUE dated on 2019-10-01: Stifel Initiates Coverage On bluebird bio with Hold Rating, Announces \$109 Price Target

Financial news for BLUE dated on 2019-09-18: bluebird bio Highlights Presentation Of Updated Data From Phase 2/3 Study Of Lenti-D Gene Therapy For Cerebral Adrenoleukodystrophy At European Pediatric Neurology Society Congress

Financial news for BLUE dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for BLUE dated on 2019-09-15: The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Financial news for BLUE dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for BLUE dated on 2019-08-12: Benzinga's Top Upgrades, Downgrades For August 12, 2019

Financial news for BLUE dated on 2019-08-12: William Blair Downgrades bluebird bio to Market Perform

Financial news for BLUE dated on 2019-08-06: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$136

Financial news for BLUE dated on 2019-08-01: bluebird bio Q2 EPS \$(3.55) Misses \$(3.06) Estimate, Sales \$13.3M Beat \$10.89M Estimate

Financial news for BLUE dated on 2019-07-25: 35 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for BLUE dated on 2019-06-18: Maxim Group Upgrades bluebird bio to Buy, Announces \$160 Price Target

Financial news for BLUE dated on 2019-06-17: BMO Capital Maintains Outperform on bluebird bio, Lowers Price Target to \$163

Financial news for BLUE dated on 2019-06-14: Consider These New ETFs In A Megatrend Search

Financial news for BLUE dated on 2019-06-14: Bluebird Bio shares are trading lower after the company presented data for its LentiGlobin gene therapy for sickle cell disease.

Financial news for BLUE dated on 2019-06-14: The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

Financial news for BLUE dated on 2019-06-14: bluebird bio Presents New Data for LentiGlobin Gene Therapy for Sickle Cell Disease at #EHA19

Financial news for BLUE dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for BLUE dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for BLUE dated on 2019-06-03: Bluebird Bio Announces EU Conditional Marketing Authorization For ZYNTEGLO Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent b-Thalassemia Who Do Not Have b0/b0 Genotype

Financial news for BLUE dated on 2019-05-30: Jim Cramer Weighs In On Anadarko, Micron And More

Financial news for BLUE dated on 2019-05-16: bluebird bio To Present New Data From Studies Of LentiGlobin For Transfusion-Dependent b-thalassemia, LentiGlobin Gene Therapy for Sickle Cell Disease at the 24th EHA Congress

Financial news for BLUE dated on 2019-05-15: Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade

Financial news for BLUE dated on 2019-05-15: 10 Biggest Price Target Changes For Wednesday

Financial news for BLUE dated on 2019-05-15: Benzinga's Top Upgrades, Downgrades For May 15, 2019

Financial news for BLUE dated on 2019-05-15: Wedbush Downgrades bluebird bio, Inc. - Common Stock to Neutral, Lowers Price Target to \$131

Financial news for BLUE dated on 2019-05-02: bluebird bio Q1 EPS \$(2.99) Misses \$(2.8) Estimate, Sales \$12.47M Miss \$13.24M Estimate

Financial news for BLUE dated on 2019-05-01: Celgene And Bluebird Bio Highlight Results From Ongoing Multicenter Phase 1 Study Of bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine

Financial news for BLUE dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for BLUE dated on 2019-04-16: Jim Cramer Weighs In On Oracle, Bluebird Bio And More

Financial news for BLUE dated on 2019-03-29: bluebird bio Issues Press Release Confirming Positive CHMP Opinion For ZYNTEGLO

Financial news for BLUE dated on 2019-03-29: EMA Panel Recommends Approval Of bluebird bio's Zynteglo For Treatment Of A Type Of Blood Disorder With Conditions

Financial news for BLUE dated on 2019-03-25: Adam Feuerstein Tweets: \$BLUE the EMA's CHMP issued a positive opinion (approval recommendation) of lentiGlobin gene therapy for transfusion-dependent beta thalassemia. Brand name: Zyntelgo.

Financial news for BLUE dated on 2019-03-11: 'The sickle cell gene therapy featured on 60 Minutes last night was \$BLUE LentiGlobin. I wasn't sure bc Bluebird was not mentioned, had no involvement in the story...' -Tweet From STAT News' Adam Feuerstein

Financial news for BLUE dated on 2019-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2019

Financial news for BLUE dated on 2019-03-05: Leerink Swann Downgrades bluebird bio to Market Perform

Financial news for BLUE dated on 2019-02-26: Benzinga's Top Upgrades, Downgrades For February 26, 2019

Financial news for BLUE dated on 2019-02-26: Cowen & Co. Initiates Coverage On bluebird bio with Outperform Rating

Financial news for BLUE dated on 2019-02-26: 72 Biggest Movers From Yesterday

Financial news for BLUE dated on 2019-02-25: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2019-02-25: Shares of gene therapy companies are trading higher after Roche announced it would acquire Spark Therapeutics for \$114.50 per share in cash.

Financial news for BLUE dated on 2019-02-25: Bluebird Bio shares are trading higher in sympathy with Roche's acquisition of Spark Therapeutics earlier Monday.

Financial news for BLUE dated on 2019-02-22: The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

Financial news for BLUE dated on 2019-02-21: bluebird bio Q4 EPS \$(2.72) Beats \$(2.86) Estimate, Sales \$19.24M Beat \$8.12M Estimate

Financial news for BLUE dated on 2019-02-11: Bluebird Bio Announces Chip Baird CFO, Current CFO to Remain with Company in New Role

Financial news for BLUE dated on 2019-01-28: Goldman Sachs Steps To The Sidelines On Crispr Therapeutics

Financial news for BLUE dated on 2019-01-23: 10 Biggest Price Target Changes For Wednesday

Financial news for BLUE dated on 2019-01-23: Canaccord Genuity Maintains Buy on bluebird bio, Lowers Price Target to \$161

Financial news for BLUE dated on 2019-01-07: Bluebird Bio shares are trading higher after the company announced a collaboration with Inhibrx to research, develop and commercialize CAR T cell immunotherapies.

Financial news for BLUE dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for BLUE dated on 2018-12-20: Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation

Financial news for BLUE dated on 2018-12-20: Raymond James Initiates Coverage On bluebird bio with Strong Buy Rating

Financial news for BLUE dated on 2018-12-19: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$125

Financial news for BLUE dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for BLUE dated on 2018-12-06: 10 Biggest Price Target Changes For Thursday

Financial news for BLUE dated on 2018-12-06: Benzinga's Top Upgrades, Downgrades For December 6, 2018

Financial news for BLUE dated on 2018-12-06: PiperJaffray Downgrades bluebird bio to Neutral, Lowers Price Target to \$120

Financial news for BLUE dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for BLUE dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for BLUE dated on 2018-12-04: bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at ASH 2018

Financial news for BLUE dated on 2018-12-04: bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent b-Thalassemia with CHP at ASH 2018

Financial news for BLUE dated on 2018-12-03: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2018-12-03: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2018-12-02: bluebird bio, Celgene Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH 2018

Financial news for BLUE dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for BLUE dated on 2018-12-02: bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent b-Thalassemia and Sickle Cell Disease at ASH 2018

Financial news for BLUE dated on 2018-11-28: Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

Financial news for BLUE dated on 2018-11-28: Benzinga's Top Upgrades, Downgrades For November 28, 2018

Financial news for BLUE dated on 2018-11-28: Leerink Swann Initiates Coverage On

bluebird bio with Outperform Rating, Announces \$145 Price Target

Financial news for BLUE dated on 2018-11-27: Leerink Initiates Coverage On bluebird bio With Outperform Rating, \$145 Price Target, On Rocket Pharma With Outperform Rating, \$22 Price Target

Financial news for BLUE dated on 2018-11-27: bluebird bio Option Alert: Dec 21 \$110 Puts Sweep (5) near the Bid: 1029 @ \$6.09 vs 309 OI; Ref=\$121.07

Financial news for BLUE dated on 2018-11-27: Celgene, bluebird bio Report Enrollment Completed In Pivotal KarMMa Study Of bb2121 In Patients With Relapsed, Refractory Multiple Myeloma

Financial news for BLUE dated on 2018-11-05: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$185

Financial news for BLUE dated on 2018-11-05: Janney Upgrades bluebird bio Ahead Of Sick Cell Presentation

Financial news for BLUE dated on 2018-11-05: Wedbush Maintains Outperform on bluebird bio, Lowers Price Target to \$166

Financial news for BLUE dated on 2018-11-05: Janney Capital Upgrades bluebird bio to Buy, Maintains \$170 Price Target

Financial news for BLUE dated on 2018-11-01: bluebird bio Q3 EPS \$(2.73) Beats \$(2.87) Estimate, Sales \$11.528M Beat \$7.51M Estimate

Financial news for BLUE dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for BLUE dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for BLUE dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for BLUE dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for BLUE dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for BLUE dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for BLUE dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for BLUE dated on 2018-10-15: Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to \$186

Financial news for BLUE dated on 2018-10-12: Stocks Which Set New 52-Week Low Yesterday, October 11th

Financial news for BLUE dated on 2018-10-05: bluebird bio 8-K Shows EMA Accepted Co.'s Marketing Authorization Application For LentiGlobin As Treatment For Adolescents, Adults With Transfusion-Dependent ss-Thalassemia

Financial news for BLUE dated on 2018-09-25: Jim Cramer Weighs In On Alibaba, Nucor, Total And More

Financial news for BLUE dated on 2018-09-11: bluebird bio 8-K Shows Co. COO, Susanna High, To Leave, Effective Jan. 4, 2019

Financial news for BLUE dated on 2018-09-06: Wells Fargo Securities Health Care Conference Concludes Today, Presenters Include: Universal Health Services, Tenet Healthcare, Bluebird Bio

Financial news for BLUE dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for BLUE dated on 2018-09-05: Bluebird Bio Reaches Agreement With FDA And EMA On Clinical Development Program To Support Future Marketing Applications For Lenti-D In CALD

Financial news for BLUE dated on 2018-09-02: The Week Ahead In Biotech: Conferences,



## PDUFA Dates, Clinical Trials And Earnings

Financial news for BLUE dated on 2018-08-23: UPDATE: bluebird Says Gritstone Oncology Will Receive \$20M In Upfront Payment With Added \$10M In Form Of Series C Preferred Equity Investment

Financial news for BLUE dated on 2018-08-23: bluebird bio Reports Strategic Collaboration With Gritstone Oncology For Development Of Novel Cancer Cell Therapies

Financial news for BLUE dated on 2018-08-15: Express Scripts in Talks With Biomarin Pharmaceutical, Spark Therapeutics, Bluebird Bio to have Specialty Pharmaceutical Business Exclusively Distribute Their New Hemophilia Treatments

Financial news for BLUE dated on 2018-08-06: Regeneron To Make \$100M bluebird bio Investment In Cancer Research Collaboration

Financial news for BLUE dated on 2018-08-06: Benzinga Pro's 5 Stocks To Watch Today

Financial news for BLUE dated on 2018-08-06: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2018-08-06: bluebird bio and Regeneron Announce Cancer Collaboration, Regeneron to Invest \$100M in bluebird Stock at \$238.10/Share

Financial news for BLUE dated on 2018-08-02: bluebird bio Q2 EPS \$(2.91) Misses \$(2.35) Estimate, Sales \$7.851M Miss \$9.64M Estimate

Financial news for BLUE dated on 2018-07-26: bluebird bio's LentiGlobin Gene Therapy Granted Accelerated Assessment by European Medicines Agency

Financial news for BLUE dated on 2018-07-24: bluebird bio Prices 3.3M Share Public Offering of Common Stock @\$162.50/Share

Financial news for BLUE dated on 2018-07-24: Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering

Financial news for BLUE dated on 2018-07-23: Bluebird Bio Announces \$400M Common Stock Offering

Financial news for BLUE dated on 2018-07-12: bluebird bio 8-K Shows Celgene Amended Study Protocol For KarMMa Study Of bb2121 In Patients With Relapsed, Refractory Multiple Myeloma: Dose Range For Study Will Be 150-450 x 10<sup>6</sup> CAR+ T Cells, Enrollment Raised To Up To 140 Patients

Financial news for BLUE dated on 2018-06-29: Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying

Financial news for BLUE dated on 2018-06-29: bluebird bio Option Alert: Jul 20 \$170 Calls at the Ask: 622 @ \$5.8 vs 387 OI; Earnings 8/1 After Close [est] Ref=\$162.125

Financial news for BLUE dated on 2018-06-23: Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Financial news for BLUE dated on 2018-06-19: 8 Biggest Price Target Changes For Tuesday

Financial news for BLUE dated on 2018-06-19: Benzinga's Top Upgrades, Downgrades For June 19, 2018

Financial news for BLUE dated on 2018-06-19: Evercore ISI Group Upgrades bluebird bio to Outperform, Raises Price Target to \$230

Financial news for BLUE dated on 2018-06-15: UPDATE: bluebird bio Offers Group A, B, C, Results For LentiGlobin In Severe Sick Cell Treatment Trial

Financial news for BLUE dated on 2018-06-15: UPDATE: bluebird bio Says 'First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbAT87Q at 6 months'

Financial news for BLUE dated on 2018-06-15: bluebird bio Reports New Interim Data From Phase 1 HGB-206 Study Of LentiGlobin In Patients with Severe Sick Cell Disease; All patients (n=4) in Group C with >= 3 months follow-up consistently producing >= 30% anti-sickling HbAT87Q

Financial news for BLUE dated on 2018-06-15: 'New \$BLUE data show promising benefits for gene therapy, if they last [statnews.com/2018/06/15/blu...](http://statnews.com/2018/06/15/blu...) Your latest sickle cell and beta-thalassemia update.'

Financial news for BLUE dated on 2018-06-15: UPDATE: bluebird bio Highlights Results On HGB-207, HGB-204

Financial news for BLUE dated on 2018-06-15: UPDATE: bluebird bio Says Co. On Track To File Marketing Authorization Application In EU In 2H'18

Financial news for BLUE dated on 2018-06-15: bluebird bio Reports Presentation Of Data From Phase 1/2 HGB-204 Study In Adolescents With Transfusion-Dependent b-Thalassemia at Annual Congress of the European Hematology Association

Financial news for BLUE dated on 2018-06-10: The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Financial news for BLUE dated on 2018-06-07: Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma

Financial news for BLUE dated on 2018-06-04: Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis

Financial news for BLUE dated on 2018-06-04: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for BLUE dated on 2018-05-31: PiperJaffray Assumes bluebird bio at Overweight, Announces Price Target \$240

Financial news for BLUE dated on 2018-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for BLUE dated on 2018-05-23: bluebird bio Reports FDA Granted Breakthrough Therapy Designation To Lenti-D For Treatment Of Cerebral Adrenoleukodystrophy

Financial news for BLUE dated on 2018-05-22: UPDATE: FDA Is Planning Easier Approval For Experimental Gene Therapies

Financial news for BLUE dated on 2018-05-22: Watching Gene Therapy Stocks Amid Report FDA Could Allow Gene Therapy Approval On Surrogate Endpoints

Financial news for BLUE dated on 2018-05-17: Adam Feuerstein Tweet: \$BLUE -- I saw some confusion last night re: #ASCO18 abstract for bb2121. To clarify, no new data in the ASCO abstract, including patient deaths. Already known. The update will be presented at the meeting.

Financial news for BLUE dated on 2018-05-03: BMO Capital Maintains Outperform on bluebird bio, Lowers Price Target to \$216.00

Financial news for BLUE dated on 2018-05-02: bluebird bio Q1 EPS \$(2.31) Misses \$(2.07) Estimate, Sales \$15.957M Beat \$5.59M Estimate

Financial news for BLUE dated on 2018-04-09: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2018-04-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2018-03-28: UPDATE: bluebird, Celgene To Share 50% Of US Costs, Profits, bluebird Will Receive Milestone, Royalty Payments In Ex-US Sales

Financial news for BLUE dated on 2018-03-28: bluebird bio, Celgene Reports Deal To Co-Develop, Promote Anti-BCMA CAR T Cell Therapy bb2121 In US

Financial news for BLUE dated on 2018-03-21: Morgan Stanley Maintains Equal-Weight on bluebird bio, Raises Price Target to \$209.00

Financial news for BLUE dated on 2018-03-20: bluebird bio Shares Continue Lower Following Word Of Negative Comments From Favus On Fri., Response From STAT News' Adam Feuerstein: Stock Down 5.9% Tues., Down 14% From Thurs. Close; Not Seeing New News To Justify Move Lower Tues.

Financial news for BLUE dated on 2018-03-16: Adam Feuerstein Tweets: Well... honestly, Favus is just making a trading call. Look at \$BLUE chart. Not hard to do with an important catalyst coming.

Financial news for BLUE dated on 2018-03-16: Adam Feuerstein Tweets (2/2): High

expectations for BCMA program. Could see more patient relapses. \$CELG JUNO deal a negative.

Financial news for BLUE dated on 2018-03-16: Adam Feuerstein Tweets (1/2): I read the Favus note on \$BLUE. He basically sets up the stock as a short trade going into ASCO: Stock price flying.

Financial news for BLUE dated on 2018-03-15: Barclays Global Healthcare Conference Concludes Today, Presenters Include: Tenet Healthcare, bluebird bio, and Revance Therapeutics

Financial news for BLUE dated on 2018-03-14: Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued

Financial news for BLUE dated on 2018-03-14: Benzinga's Top Upgrades, Downgrades For March 14, 2018

Financial news for BLUE dated on 2018-03-14: Janney Capital Initiates Coverage On bluebird bio with Neutral Rating, Announces \$220.00 Price Target

Financial news for BLUE dated on 2018-03-05: William Blair: Bluebird Bio Could See Another 'Blue Ribbon Year' In 2018

Financial news for BLUE dated on 2018-03-05: William Blair Initiates Coverage On bluebird bio with Outperform Rating, Announces \$242.00 Price Target

Financial news for BLUE dated on 2018-02-26: Morgan Stanley Maintains Equal-Weight on bluebird bio, Raises Price Target to \$152.00

Financial news for BLUE dated on 2018-02-22: 5 Biggest Price Target Changes For Thursday

Financial news for BLUE dated on 2018-02-22: Bank of America Maintains Neutral on bluebird bio, Raises Price Target to \$218.00

Financial news for BLUE dated on 2018-02-22: BMO Capital Maintains Outperform on bluebird bio, Raises Price Target to \$222.00

Financial news for BLUE dated on 2018-02-21: bluebird bio Reports Q4 Net Loss \$117.2M, EPS \$(2.52), Sales \$4.168M vs \$7.1M Est.

Financial news for BLUE dated on 2018-02-15: 13F From Perceptive Advisors Late Wednesday Shows Increased Stake In Abiomed, Neurocrine Biosciences, VBI Vaccines; New Stake In Agile Therapeutics, Amgen, bluebird bio, Arena Pharma, Revance Therapeutics; Exited Stake In Achaogen, OraSure Technologies

Financial news for BLUE dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for BLUE dated on 2018-01-25: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for BLUE dated on 2018-01-25: Leerink: Bluebird Bio's Catalysts Are Priced In

Financial news for BLUE dated on 2018-01-25: Benzinga's Top Upgrades, Downgrades For January 25, 2018

Financial news for BLUE dated on 2018-01-25: Celgene CEO Says Working With bluebird bio To Develop BB2121 Car-T Therapy For Myeloma Is A Top Priority And That Its Positioned To Launch 2 Car-T Therapies In Blood Cancers In Next 3 Years

Financial news for BLUE dated on 2018-01-25: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for BLUE dated on 2018-01-25: Leerink Swann Downgrades bluebird bio to Market Perform

Financial news for BLUE dated on 2018-01-24: Cara Therapeutics Shares Up 19.24% As Co. Mentioned In Earlier Opinion Piece As Potential M&A Target; Other Mentions Include: BMRN -0.66%, BLUE +3.87%, ACAD -0.3%, INCY +0.4%

Financial news for BLUE dated on 2018-01-23: Pharma M&A Picks Up Momentum

Financial news for BLUE dated on 2018-01-23: Bluebird Bio Up On Buyout Speculation After Celgene-Juno Deal

Financial news for BLUE dated on 2018-01-23: 38 Biggest Movers From Yesterday

Financial news for BLUE dated on 2018-01-22: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2018-01-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2018-01-19: A Survey Of Celgene's M&A Strategy

Financial news for BLUE dated on 2018-01-18: 44 Biggest Movers From Yesterday

Financial news for BLUE dated on 2018-01-17: Wall Street Reacts To Celgene's Reported Interest In Juno

Financial news for BLUE dated on 2018-01-17: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for BLUE dated on 2018-01-17: bluebird bio Shares Trading Up 10% Following Report Celgene In Talks To Buy Juno; bluebird Likely Being Viewed As A Sympathy Play

Financial news for BLUE dated on 2018-01-09: From JP Morgan Healthcare Conference: bluebird bio Expecting Filing for US, EU Approval Of B2121 For Multiple Myeloma In '19

Financial news for BLUE dated on 2018-01-09: bluebird CEO Sees 3 Regulatory Filings By End Of 2019

Financial news for BLUE dated on 2018-01-09: JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics

Financial news for BLUE dated on 2018-01-08: Adam Feuerstein Tweets: \$BLUE EMA filing for beta-thal gene therapy will be towards end of year. A bit later than some had hoped for.

Financial news for BLUE dated on 2018-01-04: Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam

Financial news for BLUE dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for BLUE dated on 2017-12-21: Oppenheimer Initiates Coverage On bluebird bio with Perform Rating

Financial news for BLUE dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for BLUE dated on 2017-12-14: ICYMI: T-Mobile Terrorizes Telecom Space, 2017 ASH Recap, Bitcoin Continues To Dominate The News Cycle

Financial news for BLUE dated on 2017-12-14: 30 Biggest Movers From Yesterday

Financial news for BLUE dated on 2017-12-13: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for BLUE dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for BLUE dated on 2017-12-13: Analyst Doubts Bluebird Bio Shares -- Up 200% In 2017 -- Can Fly Much Higher

Financial news for BLUE dated on 2017-12-13: Benzinga's Top Upgrades, Downgrades For December 13, 2017

Financial news for BLUE dated on 2017-12-13: Maxim Group Downgrades bluebird bio to Hold

Financial news for BLUE dated on 2017-12-13: A Peek Into The Markets: U.S. Stock Futures Edge Higher; Fed Decision In Focus

Financial news for BLUE dated on 2017-12-13: bluebird bio Prices ~3.2M Share Offering @\$185/Share

Financial news for BLUE dated on 2017-12-12: ICYMI: Blockchain, Bitcoin, And Biotech

Financial news for BLUE dated on 2017-12-12: 42 Biggest Movers From Yesterday

Financial news for BLUE dated on 2017-12-12: 7 Stocks To Watch For December 12, 2017

Financial news for BLUE dated on 2017-12-11: 7 Stocks Moving In Monday's After-Hours Session

Financial news for BLUE dated on 2017-12-11: 11 Biotech Stocks Moving From ASH 2017

Financial news for BLUE dated on 2017-12-11: bluebird bio Reports Offering Of \$600M In Common Shares

Financial news for BLUE dated on 2017-12-11: Mid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike Higher

Financial news for BLUE dated on 2017-12-11: 3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Financial news for BLUE dated on 2017-12-11: Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure

Financial news for BLUE dated on 2017-12-11: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2017-12-11: Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting

Financial news for BLUE dated on 2017-12-11: Mid-Morning Market Update: Markets Edge Higher; 3M To Sell Communication Markets Division For \$900M

Financial news for BLUE dated on 2017-12-11: 5 Biggest Price Target Changes For Monday

Financial news for BLUE dated on 2017-12-11: Benzinga's Top Upgrades, Downgrades For December 11, 2017

Financial news for BLUE dated on 2017-12-11: After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target

Financial news for BLUE dated on 2017-12-11: bluebird bio Reports Updated Data From HGB-205 Study Of LentiGlobin Gene Therapy In Patients With Severe Sickle Cell Disease, Transfusion-Dependent ss-Thalassemia

Financial news for BLUE dated on 2017-12-11: Suntrust Raises Price Target On bluebird bio From \$163 To \$223 Based On 'Robust' Durability Data Presented On All Programs At ASH Conference, Increases Probability Of Success In SCD Program From 40% to 60% And Car-T Program from 35% to 55%

Financial news for BLUE dated on 2017-12-11: Jefferies Upgrades bluebird bio to Buy

Financial news for BLUE dated on 2017-12-11: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2017-12-11: Adam Feuerstein Tweets: \$BLUE had a good #ASH17. BCMA CAR-T - [statnews.com/2017/12/10/car...](http://statnews.com/2017/12/10/car...) beta-thal and sickle cell gene therapy - [statnews.com/2017/12/11/blu...](http://statnews.com/2017/12/11/blu...)

Financial news for BLUE dated on 2017-12-10: Bluebird Bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin Gene Therapy in Severe Sickle Cell Disease at #ASH2017

Financial news for BLUE dated on 2017-12-10: Bluebird Bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Tta from Clinical Studies of LentiGlobin(tm) Gene Therapy in Transfusion-Dependent b-Thalassemia at #ASH2017

Financial news for BLUE dated on 2017-12-07: Bluebirdbio and TC BioPharm to Collaborate to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy, Bluebird to Make a \$16M Upfront Payment

Financial news for BLUE dated on 2017-12-05: Benzinga's Top Upgrades, Downgrades For December 5, 2017

Financial news for BLUE dated on 2017-12-05: Canaccord Genuity Initiates Coverage On bluebird bio with Buy Rating, Announces \$202.00 Price Target

Financial news for BLUE dated on 2017-11-30: Bluebird Bio Shares Up 3.56%; Earlier Maxim Group Maintained A Buy Rating On The Co., Raising Price Target From \$170 to \$200, Citing Reduced Risk and Saying Valuation Hasn't Peaked

Financial news for BLUE dated on 2017-11-29: Bluebird Bio Acquires a manufacturing Facility in North Carolina, Terms Not Disclosed

Financial news for BLUE dated on 2017-11-16: Celgene Corporation, bluebird bio Report bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma

Financial news for BLUE dated on 2017-11-16: bluebird bio Reports First Patient Treated In HGB-212, Phase 3 Study of LentiGlobin(tm) in Patients with TDT, b0/b0 Genotype

Financial news for BLUE dated on 2017-11-14: 13F Filing From Baker Bros Shows Increased Stake In Array BioPharma, Ascendis Pharma, BioCryst Pharmaceuticals, Slightly Reduced Stake In Bluebird Bio

Financial news for BLUE dated on 2017-11-14: Shares Of bluebird bio Moving Higher In Late Afternoon Trading, Now Positive For The Day, Up 2% At \$157.64 On No Apparent News

Financial news for BLUE dated on 2017-11-14: Omega Advisors Dissolve Stake In bluebird bio

Financial news for BLUE dated on 2017-11-08: Barclays: Editas Medicine On Track To File New Drug App Next Year

Financial news for BLUE dated on 2017-11-06: 9 Notable Biotechs Presenting At This Year's ASH Meeting

Financial news for BLUE dated on 2017-11-06: Evercore ISI Group Downgrades bluebird bio to In-Line

Financial news for BLUE dated on 2017-11-03: SunTrust Raises bluebird Price Target From \$108 To \$163, Firm Says BCMA Creates Significant Value And That ASH 2017 Is Next Major Catalyst For Co.

Financial news for BLUE dated on 2017-11-03: Benzinga's Top Upgrades, Downgrades For November 3, 2017

Financial news for BLUE dated on 2017-11-03: Morgan Stanley Upgrades bluebird bio to Equal-Weight

Financial news for BLUE dated on 2017-11-02: Benzinga's Top Upgrades, Downgrades For November 2, 2017

Financial news for BLUE dated on 2017-11-02: BTIG Research Upgrades bluebird bio to Buy

Financial news for BLUE dated on 2017-11-01: Bluebird Bio Price Target Bumped To \$58 On Directional Improvements

Financial news for BLUE dated on 2017-11-01: Bluebird Bio Sharply Higher After Mixed Q3 Report

Financial news for BLUE dated on 2017-11-01: bluebird bio Reports Q3 EPS \$(1.73) vs \$(1.71) Est., Sales \$7.711M vs \$7.07M Est.

Financial news for BLUE dated on 2017-10-17: 35 Biggest Movers From Yesterday

Financial news for BLUE dated on 2017-10-16: 4 Biotechs Boosted By Spark Therapeutic's FDA News

Financial news for BLUE dated on 2017-10-16: The BLUE And The BOLD; Analyst Suggests Pair Trade Ahead Of Year-End Catalysts

Financial news for BLUE dated on 2017-10-16: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for BLUE dated on 2017-10-16: Benzinga's Top Upgrades, Downgrades For October 16, 2017

Financial news for BLUE dated on 2017-10-16: Evercore ISI Group Upgrades bluebird bio to Outperform

Financial news for BLUE dated on 2017-10-11: Benzinga's Top Upgrades, Downgrades For October 11, 2017

Financial news for BLUE dated on 2017-10-11: Jefferies Downgrades bluebird bio to Hold

Financial news for BLUE dated on 2017-10-04: UPDATE: bluebird bio's Publication In NEJM Show 'No engraftment failure, GVHD or life-threatening infections occurred; no evidence of insertional oncogenesis'

Financial news for BLUE dated on 2017-10-04: bluebird bio Reports Publication Of Interim Data From Starbeam Study Of Lenti-DTM Drug Product For Patients With CALD: '15/17 (88%) of the patients infused with Lenti-D drug product remain alive and free of major functional disabilities'

Financial news for BLUE dated on 2017-10-02: 12 Biggest Mid-Day Losers For Monday

Financial news for BLUE dated on 2017-10-02: Bluebird Bio's Wings Clipped, Morgan Stanley Downgrades

Financial news for BLUE dated on 2017-10-02: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2017-10-02: Morgan Stanley Downgrades bluebird bio to Underweight

Financial news for BLUE dated on 2017-09-28: bluebird bio Announces 1st Patient Treated In Phase 1 Study of BB21217

Financial news for BLUE dated on 2017-09-13: Morgan Stanley Healthcare Conference Concludes Today, Presenters Include Ironwood Pharmaceuticals, Sage Therapeutics, Pfizer, TherapeuticsMD, Alnylam, bluebird bio, and Cigna

Financial news for BLUE dated on 2017-09-13: bluebird bio Reports First Patient Treated In Expansion Cohort Of CRB-401 Phase 1 Study

Financial news for BLUE dated on 2017-09-09: Benzinga's Bulls And Bears For The Past Week: Disney, GE, Tesla And More

Financial news for BLUE dated on 2017-09-07: Breaking Down Barclays' New Bullish Calls On Biotech

Financial news for BLUE dated on 2017-09-07: Wells Fargo Healthcare Conference Concludes Today, Presenters Include: Foundation Medicine, Tenet Healthcare, bluebird bio, Envision Healthcare, Ironwood Pharmaceuticals, Quorum Health, and Concert Pharmaceuticals

Financial news for BLUE dated on 2017-09-07: Barclays Initiates Coverage On bluebird bio with Overweight Rating, Announces \$151.00 Price Target

Financial news for BLUE dated on 2017-09-05: Why It's Useful To Know A Company's Competitors When Trading

Financial news for BLUE dated on 2017-08-28: 18 Biggest Mid-Day Gainers For Monday

Financial news for BLUE dated on 2017-08-28: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2017-08-25: From A(erie) To Z(ynherba): Biotech Catalysts Lined Up For Second Half Of 2017

Financial news for BLUE dated on 2017-08-17: Benzinga's Top Upgrades, Downgrades For August 17, 2017

Financial news for BLUE dated on 2017-08-17: Evercore ISI Group Initiates Coverage On bluebird bio with In-Line Rating, Announces \$102.00 Price Target

Financial news for BLUE dated on 2017-08-15: Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet

Financial news for BLUE dated on 2017-08-14: 13F From Omega Shows Small, New Stakes In Bluebird Bio and Clovis Oncology

Financial news for BLUE dated on 2017-08-02: bluebird Reports Q2 Loss/Share \$(1.73) vs. \$(1.66) Est., Sales \$16.7M May Not Compare To \$5.21M Est.

Financial news for BLUE dated on 2017-07-27: Benzinga's Top Upgrades, Downgrades For July 27, 2017

Financial news for BLUE dated on 2017-07-27: Bernstein Initiates Coverage On bluebird bio with Market Perform Rating, Announces \$109.00 Price Target

Financial news for BLUE dated on 2017-06-30: Benzinga's Top Upgrades, Downgrades For June 30, 2017

Financial news for BLUE dated on 2017-06-30: After Bluebird's 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral

Financial news for BLUE dated on 2017-06-30: BTIG Research Downgrades bluebird bio to Neutral

Financial news for BLUE dated on 2017-06-27: Here's The Beef With Bluebird's Starbeam Study Results

Financial news for BLUE dated on 2017-06-26: UPDATE: bluebird bio Says Expansion Cohort Enrolling Added Patients To Gain European Manufacturing Experience

Financial news for BLUE dated on 2017-06-26: bluebird bio Reports \$350M Common Stock Offering

Financial news for BLUE dated on 2017-06-26: UPDATE: bluebird bio Says 88% Of Patients In Initial Study Cohort Remain Free Of MFDs At 24 Months

Financial news for BLUE dated on 2017-06-26: 8-K from bluebird bio Shows Topline Interim Data From Starbeam Study Of Lenti-D Product In CALD

Financial news for BLUE dated on 2017-06-23: 12 Biggest Mid-Day Losers For Friday

Financial news for BLUE dated on 2017-06-23: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for BLUE dated on 2017-06-23: UPDATE: bluebird bio Says HGB-205 In Severe Sick Cell Showed Clinically Meaningful Improvement In Symptoms

Financial news for BLUE dated on 2017-06-23: bluebird bio Offers New Data From HGB-205 Study Of LentiGlobin Drug Product In Patients With TDT, SCD: 3 Patients Have Discontinued Iron Chelation

Financial news for BLUE dated on 2017-06-23: bluebird bio Reports Early Data From Phase 3 HGB-207 Study Of LentiGlobin Drug Product: DP VCN, LVV+ In HGB-207 Consistently Higher Than In HGB-204 With Median DP VCN Of 3.0

Financial news for BLUE dated on 2017-06-21: Adam Feuerstein Highlights STAT News Article In Tweet 'Timely w/ \$GBT \$BLUE updates imminent --> W/ rapper's death, harsh spotlight on slow progress against sickle cell'

Financial news for BLUE dated on 2017-06-16: bluebird bio Shares Down 1.5% Following Mid-Day Downgrade From Standpoint Research From Buy To Reduce

Financial news for BLUE dated on 2017-06-16: Standpoint Research Downgrades bluebird bio to Reduce

Financial news for BLUE dated on 2017-06-09: Jefferies Health Care Conference Concludes Today, Presenters Include: Mazor Robotic, bluebird bio, and Ocular Therapeutix

Financial news for BLUE dated on 2017-06-08: The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired

Financial news for BLUE dated on 2017-06-08: Companies Holding Shareholder Meetings Today Include: Aerie Pharma, Agile Therapeutics, bluebird bio, Bojangles, Comcast, Clovis Oncology, Etsy, Egalet, Dave And Busters, Ingersoll-Rand, Priceline, Lululemon, Rent-A-Center, Splunk, & Zoe's Kitchen

Financial news for BLUE dated on 2017-06-07: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for BLUE dated on 2017-06-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLUE dated on 2017-06-06: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for BLUE dated on 2017-06-06: bluebird Shares Showing Weakness As Traders Pass Around Vague Reports Of Potential Undisclosed Lawsuit

Financial news for BLUE dated on 2017-06-06: Attention Bluebird Bio Investors: Analyst Sees Upside Following Strong Therapy Results

Financial news for BLUE dated on 2017-06-06: 5 Biggest Price Target Changes For Tuesday

Financial news for BLUE dated on 2017-06-06: Benzinga's Top Upgrades, Downgrades For June 6, 2017



Financial news for BLUE dated on 2017-06-06: The Market In 5 Minutes

Financial news for BLUE dated on 2017-06-06: BMO Capital Upgrades bluebird bio to Outperform, Raises Price Target to \$108.00

Financial news for BLUE dated on 2017-06-05: 12 Biggest Mid-Day Gainers For Monday

Financial news for BLUE dated on 2017-06-05: Bluebird Bio and Cengage Gives Update on Study of bb2121 Anti-BCMA CAR T Cell Therapy

Financial news for BLUE dated on 2017-05-30: Standpoint Research Initiates Coverage On bluebird bio with Buy Rating, Announces \$110.00 Price Target

Financial news for BLUE dated on 2017-05-03: bluebird bio Reports Q1 EPS \$(1.68) vs \$(1.78) Est., Sales \$6.832M vs \$2.12M Est.

Financial news for BLUE dated on 2017-05-02: bluebird bio Reports Entered Into Lentiviral Vector Patent License Deal with Glaxo for Commercialization of Gene Therapies

Financial news for BLUE dated on 2017-05-02: Bluebird Bio to License IP to Novartis

Financial news for BLUE dated on 2017-04-18: Adam Feuerstein Tweets: \$BLUE (short) vs \$BLCM (long) report circulating today filled w/ errors and misleading statements. First posted on Seeking Alpha April 10.

Financial news for BLUE dated on 2017-04-18: Pluvia Securities Out With Long/Short Trade Idea, Bellicum Long and Bluebird Bio Short As Firm Says Bellicum Pipeline Beats/Obsoletes BLUE's 3 Lead Drug Candidates

Financial news for BLUE dated on 2017-03-14: Barclays Global Healthcare Conference Begins Today; Presenters Include Johnson & Johnson, Alnylam, Axovant, Paraxel, Gilead, bluebird bio, Envision Healthcare, & Tenet Healthcare

Financial news for BLUE dated on 2017-03-08: bluebird bio Shares Spiking Higher

Financial news for BLUE dated on 2017-03-07: Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio

Financial news for BLUE dated on 2017-03-01: bluebird bio Reports Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine

Financial news for BLUE dated on 2017-02-28: Maxim Group Downgrades bluebird bio To Hold

Financial news for BLUE dated on 2017-02-27: Hearing bluebird bio Downgraded From Buy To Hold At Maxim

Financial news for BLUE dated on 2017-02-23: Bluebird Bio Shares Could See Value Fly To \$95 As 2017 Will Be A 'Catalyst-Filled Year'

Financial news for BLUE dated on 2017-02-22: Filing from bluebird bio Shows Registration for Mixed Securities Shelf Offering, No Terms Disclosed

Financial news for BLUE dated on 2017-02-22: bluebird bio Reports Q4 EPS \$(1.88) vs \$(1.86) Est., Sales \$1.552M vs \$1.76M Est.

Financial news for BLUE dated on 2017-02-14: 13F from Cooperman's Omega Shows New 50K Shares Stake in bluebird bio

Financial news for BLUE dated on 2017-02-06: 15 Biggest Mid-Day Losers For Monday

Financial news for BLUE dated on 2017-02-06: BlueBird Bio Wounded After Roth Downgrade

Financial news for BLUE dated on 2017-02-06: The Market In 5 Minutes: One For The Thumb

Financial news for BLUE dated on 2017-02-06: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for BLUE dated on 2017-02-06: Roth Capital Downgrades bluebird bio To Neutral

Financial news for BLUE dated on 2017-02-03: Piper's Chief Technical Analyst: This Market Is Entering A New Era

Financial news for BLUE dated on 2017-02-03: UPDATE: bluebird bio Says 'LentiGlobin™ drug product had a vector copy number (DP VCN) of 3.3 copies/diploid genome, with 83% of cells lentiviral vector sequence positive'

Financial news for BLUE dated on 2017-02-03: bluebird bio Reports First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study in Patients with Sever Sickle Cell Disease

Financial news for BLUE dated on 2017-02-02: Piper's Johnson Highlights Belief Some Healthcare Names May Have Hit Near-Term Bottom, Says Likes Celgene, bluebird bio

Financial news for BLUE dated on 2017-01-11: Vetr Crowd Upgrades Bluebird After Trump Presser

Financial news for BLUE dated on 2017-01-09: TheStreet's Adam Feuerstein Tweets '\$CELG spending a lot of time talking up pipeline from partners. \$BLUE \$XLRN etc. #JPM17'

Financial news for BLUE dated on 2017-01-09: The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know

Financial news for BLUE dated on 2016-12-15: bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

Financial news for BLUE dated on 2016-12-14: bluebird bio Announces First Patient Treated with LentiGlobin™ Drug Product in Northstar-2 Phase 3 Trial of Patients with Transfusion-Dependent  $\beta$ -Thalassemia

Financial news for BLUE dated on 2016-12-13: The Market In 5 Minutes: Oil Chugs Higher Amid Tillerson News

Financial news for BLUE dated on 2016-12-13: Blue Bird Q4 EPS \$0.49 vs \$0.42 Est, Revenue \$286.4M vs \$291.3M Est

Financial news for BLUE dated on 2016-12-09: Biotech Winners And Losers From ASH Conference

Financial news for BLUE dated on 2016-12-07: 18 Biggest Mid-Day Losers For Wednesday

Financial news for BLUE dated on 2016-12-07: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLUE dated on 2016-12-07: bluebird bio Prices ~3.289M Share Offering @\$76/Share

Financial news for BLUE dated on 2016-12-06: bluebird bio Announces Proposed Public Offering of \$200M Common Stock

Financial news for BLUE dated on 2016-12-06: 8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting

Financial news for BLUE dated on 2016-12-05: bluebird bio Provides Updates on HSC Gene Therapy Programs

Financial news for BLUE dated on 2016-12-05: American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena

Financial news for BLUE dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for BLUE dated on 2016-12-03: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent

Financial news for BLUE dated on 2016-12-02: bluebird bio Names Susanna High COO

Financial news for BLUE dated on 2016-12-01: Bluebird News A Positive For Juno, Kite Pharma

Financial news for BLUE dated on 2016-12-01: Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG

Financial news for BLUE dated on 2016-12-01: Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results

Financial news for BLUE dated on 2016-12-01: 18 Biggest Mid-Day Gainers For Thursday

Financial news for BLUE dated on 2016-12-01: Technical Alert: Bluebird Bio Soars After Encouraging Myeloma Data

Financial news for BLUE dated on 2016-12-01: Mid-Morning Market Update: Markets Mostly Higher; Dollar General Profit Misses Views

Financial news for BLUE dated on 2016-12-01: Heat Biologics Cools Off, Bluebird Bio Heats Up

Financial news for BLUE dated on 2016-12-01: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for BLUE dated on 2016-12-01: Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating

Financial news for BLUE dated on 2016-11-30: Bluebird Bio Shares +22% After Hours Following Release of Positive Data on Relapsed/Refractory Multiple Myeloma Study

Financial news for BLUE dated on 2016-11-30: UPDATE: 6 of 6 Patients In 2nd & 3rd bluebird Cohorts Achieved Objective Response, Overall Response Rate Is 78%; No Grade 3 or 4 Cytokine Release Syndrome Or Neurotoxicity Observed

Financial news for BLUE dated on 2016-11-30: Adam Feuerstein @adamfeuerstein Tweet: \$BLUE \$CELG T-Cell Therapy Eliminates Multiple Myeloma with Minimal Side Effects thestreet.com/story/13909407

Financial news for BLUE dated on 2016-11-30: bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma

Financial news for BLUE dated on 2016-11-30: Adam Feuerstein @adamfeuerstein Tweet: \$BLUE \$CELG anti-BCMA CAR-T data will be out tonight at 6 pm ET. Just FYI.

Financial news for BLUE dated on 2016-11-29: PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio

Financial news for BLUE dated on 2016-11-11: Benzinga's Top Initiations

Financial news for BLUE dated on 2016-11-11: BMO Capital Initiates Coverage On bluebird bio, Inc. - Common Stock at Market Perform, Announces \$61.00

Financial news for BLUE dated on 2016-11-03: BlueBird Bio Inc Lower After Q3 Report

Financial news for BLUE dated on 2016-11-03: Bluebird Abstracts From Data Presentation At American Society Of Hematology Mtg Now Available

Financial news for BLUE dated on 2016-11-02: Bluebird Bio Reports Q3 Loss/Share \$2.07, Rev \$1.552M vs \$1.78M Est

Financial news for BLUE dated on 2016-10-18: bluebird bio Shares Spike Higher Off Session Lows, Off \$55.50 Level; Stock Now Up 0.8%; BZ NOTE: Watch for Near-Term Profit Taking as Traders Passing Around Unconfirmed Takeover Chatter

Financial news for BLUE dated on 2016-10-14: 15 Biggest Mid-Day Losers For Friday

Financial news for BLUE dated on 2016-10-14: Bluebird Bio Shares Down 10%; Cantor Downgrades Stock To Sell

Financial news for BLUE dated on 2016-10-14: Technical Alert: Bluebird Bio Wounded After Cantor Fitzgerald Downgrade

Financial news for BLUE dated on 2016-10-14: 10 Biggest Price Target Changes For Friday

Financial news for BLUE dated on 2016-10-14: Benzinga's Top Downgrades

Financial news for BLUE dated on 2016-10-14: Tailwinds Continue To Hold The Street's Gaze Toward Bluebird Bio Aloft

Financial news for BLUE dated on 2016-10-14: Bluebird's Gene Therapy Is Firing On All Cylinders

Financial news for BLUE dated on 2016-10-14: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for BLUE dated on 2016-10-14: Favorable FDA Pathway Should Keep Bluebird's Clinical Studies Flying Straight

Financial news for BLUE dated on 2016-10-14: Cantor Fitzgerald Downgrades bluebird bio, Inc. - Common Stock to Sell

Financial news for BLUE dated on 2016-10-13: Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy

Financial news for BLUE dated on 2016-10-13: bluebird bio Reports Presentation That Focuses On Potential Improvements, Updates To Protocol For HGB-206 Trial, and Regulatory Plans

Financial news for BLUE dated on 2016-10-11: Jefferies Gene Editing/Gene Therapy Summit Commences Today With Presenters Including bluebird bio, Audentes Therapeutics, Spark Therapeutics, Sangamo Biosciences, And uniQure

Financial news for BLUE dated on 2016-09-30: BZ NOTE: Recent Stength In bluebird May Be Due To Chatter That Company Canceled Out Of A Upcoming Conference, bluebird bio Spokesperson Confirms To Benzinga That They Are Attending Jefferies Gene Therapy Conference

Financial news for BLUE dated on 2016-09-29: Maxim Raises Target On bluebird bio From \$85 To \$100, Maintains Buy Rating

Financial news for BLUE dated on 2016-09-29: bluebird bio, Medigene Announce Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherap; Medigene to Receive Upfront Payment of \$15M

Financial news for BLUE dated on 2016-09-22: Roth Capital Assumes bluebird bio at Buy

Financial news for BLUE dated on 2016-09-21: bluebird Reports LentiGlobin Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency's PRIME Program

Financial news for BLUE dated on 2016-09-15: 15 Biggest Mid-Day Gainers For Thursday

Financial news for BLUE dated on 2016-09-15: Benzinga's Volume Movers

Financial news for BLUE dated on 2016-09-15: Adam Feuerstein Tweets: \$BLUE on fire in September. I hear investor conference 1x1s have gone well.

Financial news for BLUE dated on 2016-09-15: Goldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List

Financial news for BLUE dated on 2016-09-15: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for BLUE dated on 2016-09-15: Goldman Sachs Maintains Buy on bluebird bio, Maintains \$135.00 PT, Added To Conviction Buy List

Financial news for BLUE dated on 2016-09-08: TheStreet's Adam Feuerstein Publishes 'Bluebird Improves its Gene Therapy, Removing an Investor Concern'

Financial news for BLUE dated on 2016-09-08: Adam Feuerstein @adamfeuerstein Tweet: New, enhanced gene therapy manufacturing process under current IND. Wipes out one of Street's concerns. \$BLUE

Financial news for BLUE dated on 2016-09-08: bluebird bio Opens Phase 3 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia

Financial news for BLUE dated on 2016-09-07: Goldman's 7 Favorite Biotech Ideas For 2016

Financial news for BLUE dated on 2016-09-07: Bluebird Heading Into 'Catalyst-Rich' Second Half Of The Year

Financial news for BLUE dated on 2016-08-18: Clear Skies For Bluebird Bio To Enter A New Inflection Point

Financial news for BLUE dated on 2016-08-03: bluebird bio Reports Q2 EPS \$(1.59) vs. Est. \$(1.44), Rev. \$1.552M vs. Est. \$2.2M

Financial news for BLUE dated on 2016-07-08: These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold

Financial news for BLUE dated on 2016-07-07: BlueBid Bio Sells Off to Low of \$45.08 on Juno Clinical Hold News

Financial news for BLUE dated on 2016-06-02: Bluebird Bio Initiated Hold At Cantor Fitzgerald, Decides To Await Additional Data

Financial news for BLUE dated on 2016-06-02: Cantor Fitzgerald Initiates Coverage on bluebird bio at Hold, Announces \$42.00 PT

Financial news for BLUE dated on 2016-05-05: BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts

Financial news for BLUE dated on 2016-05-04: bluebird bio Reports Q1 EPS \$(1.52) vs \$(1.23) Est., Sales \$1.499M vs \$4M Est.

Financial news for BLUE dated on 2016-05-02: Adam Feuerstein On Biotechs: 'I Have An Itchy Trigger Finger On Hypocrisy'

Financial news for BLUE dated on 2016-04-21: Bluebird Bio's LentiD 'Hits The Mark'

Financial news for BLUE dated on 2016-04-20: Adam Feuerstein @adamfeuerstein Tweet: \$BLUE spox tells me that ASGCT abstract on Lenti-D in CALD abstractsonline.com/pp8/#!/4077/pr... listing tachycardia as an SAE is incorrect. It was Gr1.

Financial news for BLUE dated on 2016-04-20: bluebird bio To Present Interim Data On Phase 2 Starbeam Study To Evaluate Lenti-D

Financial news for BLUE dated on 2016-04-18: bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting

Financial news for BLUE dated on 2016-04-08: Goldman Is Buying: Bluebird Bio Off To 'Flying Start'

Financial news for BLUE dated on 2016-04-07: How One Analyst Is Playing The Biotech Rebound This Week

Financial news for BLUE dated on 2016-03-04: The Market In 5 Minutes: Friday, March 4, 2016

Financial news for BLUE dated on 2016-03-04: Premarket Wells Fargo Said BLUE Lenti-D Data Validates Pipeline, PiperJaffray Called Daya 'very promising'

Financial news for BLUE dated on 2016-03-04: BlueBird Bio Spikes to High of \$57.80 on Volume; May be Attributed to Positive Analyst Comments on Lenti-D Data

Financial news for BLUE dated on 2016-03-01: Benzinga's Top Initiations

Financial news for BLUE dated on 2016-03-01: BTIG Research Initiates Coverage on bluebird bio at Buy, Announces \$72.00 PT

Financial news for BLUE dated on 2016-02-25: Bluebird Bio CFO Jim DeTore to Leave

Financial news for BLUE dated on 2016-02-24: BlueBird Bio Reports Q4 EPS \$(1.29) Vs Est \$(1.11), Sales \$1.5M Vs Est \$3.21M

Financial news for BLUE dated on 2016-02-17: Bluebird Bio Gains 9% After Co. Begins New Phase 1 Study

Financial news for BLUE dated on 2016-02-17: bluebird bio Reports First Patient Has Been Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Financial news for BLUE dated on 2016-02-03: Benzinga's Top Initiations

Financial news for BLUE dated on 2016-02-03: Leerink Swann Initiates Coverage on bluebird bio at Outperform, Announces \$67.00 PT

Financial news for BLUE dated on 2016-01-05: Janney Capital Initiates Coverage on bluebird bio at Buy

Financial news for BLUE dated on 2015-12-29: 10 Biotechs Short Sellers Are Betting Against

Financial news for BLUE dated on 2015-12-17: The Top 20 Wall Street Analysts Of 2015

Financial news for BLUE dated on 2015-12-07: Mid-Afternoon Market Update: Crude Oil Declines 6%; Bluebird Bio Shares Tumble

Financial news for BLUE dated on 2015-12-07: BlueBird Bio Unable To Rebound

Financial news for BLUE dated on 2015-12-07: Notable Biotech Analyst Jason Napodano Says ASH Conference Stocks Poor Performance Today Are Due To Expectations Being Too High For The Stocks Right Now

Financial news for BLUE dated on 2015-12-07: Mid-Day Market Update: Dow Dips 150 Points; Sodastream Shares Spike Higher

Financial news for BLUE dated on 2015-12-07: Bluebird Bio Crashes Nearly 30%: What's Next?

Financial news for BLUE dated on 2015-12-07: Mid-Morning Market Update: Markets Open Lower; Keurig Green Mountain Agrees To Be Taken Private For \$92/Share

Financial news for BLUE dated on 2015-12-07: Morning Market Losers

Financial news for BLUE dated on 2015-12-07: Benzinga's Top Downgrades

Financial news for BLUE dated on 2015-12-07: Morgan Stanley Cuts bluebird bio, Slashes Price Target From \$143 To \$69

Financial news for BLUE dated on 2015-12-07: Benzinga's Top #PreMarket Losers

Financial news for BLUE dated on 2015-12-07: Bank of America Downgrades bluebird bio to Neutral

Financial news for BLUE dated on 2015-12-07: BlueBird Bio Shares Fall 28% on Mixed Sick Cell Data Results Presented at #ASH2015

Financial news for BLUE dated on 2015-12-07: Roth Capital Downgrades bluebird bio to Neutral, Lowers PT to \$62.00

Financial news for BLUE dated on 2015-12-07: Wedbush on bluebird bio: 'Treatment Challenges Highlighted by Sickest Patients Likely Increase Time to LentiGlobin Approval'; Outperform Reiterated, Target Reduced from \$165 to \$117

Financial news for BLUE dated on 2015-12-07: Key Changes To Morgan Stanley Analyst Model On bluebird bio Downgrade, Reasons For PT Slash From \$143 To \$69/Share

Financial news for BLUE dated on 2015-12-07: Morgan Stanley Analyst Believe bluebird bio Ash Conf. Data Have Turned Favorable Risk/Reward Thesis Upside Down Due To Inability Of BB305 To Consistently Produce Enough Hb In Sick Cell Patients, Removing Floor In Their Valuation

Financial news for BLUE dated on 2015-12-07: Morgan Stanley Downgrades bluebird bio to Equal-weight, Lowers PT to \$69.00

Financial news for BLUE dated on 2015-12-06: Bluebird Presenting Mixed Results from HGB-206 Studay Sunday at #ASH2015 -Adam F/The Street

Financial news for BLUE dated on 2015-12-05: bluebird bio Reports New Beta-thalassemia Major Data from Northstar Study of LentiGlobin at #ASH2015

Financial news for BLUE dated on 2015-12-04: Wells Fargo Initiates Coverage on bluebird bio at Outperform

Financial news for BLUE dated on 2015-12-03: Roth Reinstates Coverage On Bluebird Bio, Sees Massive 50% Upside

Financial news for BLUE dated on 2015-12-03: bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy

Financial news for BLUE dated on 2015-12-03: Roth Capital Assumes bluebird bio at Buy, Announces \$121.00 PT

Financial news for BLUE dated on 2015-11-18: Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks

Financial news for BLUE dated on 2015-11-18: Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Estimates

Financial news for BLUE dated on 2015-11-18: Morning Market Gainers

Financial news for BLUE dated on 2015-11-18: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2015-11-18: Goldman Sachs Initiates Coverage on bluebird bio at Buy, Announces \$165.00 PT

Financial news for BLUE dated on 2015-11-16: Wedbush's David Nierengarten Says bluebird bio's ASH Results Bode Well For Anti-BCMA Candidate bb2121

Financial news for BLUE dated on 2015-11-16: UPDATE: Wedbush's Nierengarten Sees Results from NCI-Sponsored Study of Anti-BCMA CAR-T Cells Boding Well for bluebird bio's bb2121, Expected to Enter Clinic in '16

Financial news for BLUE dated on 2015-11-16: Wedbush's Nierengarten on ASH Late-Breaker Related to BCMA CAR-T Therapy Showing Anti-Myeloma Activity: Says Sees Read Through to bluebird bio

Financial news for BLUE dated on 2015-11-16: Cooperman's Omega Liquidates Position in bluebird bio

Financial news for BLUE dated on 2015-11-05: Bluebird Bio Selling 'An Overreaction,' Data Is 'Fantastic' Says Biotech Expert

Financial news for BLUE dated on 2015-11-05: bluebird bio Shares Down 15% With Release Of ASH Abstract This Morning

Financial news for BLUE dated on 2015-11-05: UPDATE: Napodano Still Sees a 'Big Market Opportunity' for bluebird bio, 'and with the stock down 60% off the highs, I think priced in.'

Financial news for BLUE dated on 2015-11-05: UPDATE: Napodano on bluebird bio: 'the awe of a universal cure is gone, and that perception is hurting the stock'

Financial news for BLUE dated on 2015-11-05: Noted Biotech Analyst Jason Napodano Says bluebird bio Sell Off "Looks Like An Overreaction, SCD Data & Data In non-BO/BO Patient Looks Fantastic"

Financial news for BLUE dated on 2015-11-05: Andy Biotech Tweets: #ASH15 Abstracts. Tweet Has Links To Each Biotech Company's Abstract

Financial news for BLUE dated on 2015-11-05: BZ NOTE: Watch Biotech Stocks As ASH Conference Abstracts To Be Released At 9pm ET

Financial news for BLUE dated on 2015-11-04: bluebird bio Reports Q3 Loss \$1.18 vs Est Loss \$0.94, Sales \$1.32M Vs Est \$5.21M

Financial news for BLUE dated on 2015-11-03: Oppenheimer's Marai Mentions That Cellectis SA Run May Have Triggered "ASH Trades" Like bluebird bio Which Is Up 10.45% On The Day

Financial news for BLUE dated on 2015-10-21: Wedbush's Nierengarten on bluebird bio: Sees Volatility Around ASH Meeting, 'But Shares Are Discounting Too Much'; Analyst Reiterates Outperform, \$222 Target

Financial news for BLUE dated on 2015-10-20: Benzinga's Top Initiations

Financial news for BLUE dated on 2015-10-20: Oppenheimer Initiates Coverage on bluebird bio at Outperform, Announces \$162.00 PT

Financial news for BLUE dated on 2015-10-19: Here's Why Biotechs Fell On Monday

Financial news for BLUE dated on 2015-10-19: Roth Capital Defending Bluebird Bio, Says They Are Buyers Into ASH Meeting, Says Co. Is Well Positioned To Leverage Robust In-House Expertise In Gene Editing And Lentiviral Vectorology

Financial news for BLUE dated on 2015-10-19: Hearing JP Morgan Defending Bluebird Bio, Says Sell-Off Is Over-Reaction

Financial news for BLUE dated on 2015-10-19: BlueBird Bio Shares Continue To Sell Off, Down Over 15% now

Financial news for BLUE dated on 2015-10-19: Shares Of bluebirdbio Resume Trading, Now At \$82.61/Share And Spiking Higher

Financial news for BLUE dated on 2015-10-19: Bluebird Bio Resumes Trading, Rebounding A Bit From Pre-Halt Sell Off, Currently Trading \$82.39

Financial news for BLUE dated on 2015-10-19: BlueBird Bio Update On LG001 Study

Financial news for BLUE dated on 2015-10-19: bluebirdbio Trading Halted

Financial news for BLUE dated on 2015-10-19: bluebird bio Announces Presentation at Cooley's Anemia Foundation Symposium

Financial news for BLUE dated on 2015-10-19: bluebird bio Shares Selloff as Company Announces Presentation at Cooley's Anemia Foundation Symposium

Financial news for BLUE dated on 2015-10-19: BlueBird Bio Shares Selling Off

Financial news for BLUE dated on 2015-10-19: bluebirdbio Shares Falling To \$81.21/Share

Financial news for BLUE dated on 2015-10-13: Bluebird Bio Spikes to High

Financial news for BLUE dated on 2015-10-05: Bluebird Bio Upgraded At Morgan Stanley; Firm Sees 'Innovation At A Discount'

Financial news for BLUE dated on 2015-10-05: Benzinga's Top Upgrades

Financial news for BLUE dated on 2015-10-05: UPDATE: Morgan Stanley Upgrades bluebird bio, Sees 'Innovation at a Discount'

Financial news for BLUE dated on 2015-10-05: Morgan Stanley Upgrades bluebird bio to Overweight

Financial news for BLUE dated on 2015-09-22: Cramer Gives His Opinion On bluebird bio, Atmel And Time Warner Cable

Financial news for BLUE dated on 2015-09-11: BlueBird Bio Spikes to High

Financial news for BLUE dated on 2015-09-08: Benzinga's M&A Chatter for Tuesday September 8, 2015

Financial news for BLUE dated on 2015-09-08: Hearing Dealreporter Chatter On Bluebio Takeover, Says To Be Acquired By Big Pharma For \$300/Share - UNCONFIRMED

Financial news for BLUE dated on 2015-09-08: Benzinga's Top Initiations

Financial news for BLUE dated on 2015-09-08: Morgan Stanley Initiates Coverage on bluebird bio at Equal-weight, Announces \$143.00 PT

Financial news for BLUE dated on 2015-08-25: What Should Biotech Investors Do Now?

Financial news for BLUE dated on 2015-08-25: Market Panic Has Created 'Compelling' Opportunities In Biotech

Financial news for BLUE dated on 2015-08-25: Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics

Financial news for BLUE dated on 2015-08-16: Why Have Shares Of Global Blood Therapeutics Skyrocketed Since Its Debut?

Financial news for BLUE dated on 2015-08-12: Roth Capital Recommending Buying the Weakness in bluebird bio

Financial news for BLUE dated on 2015-08-11: bluebird Bio CEO Sells 125K Shares As Of August 7

Financial news for BLUE dated on 2015-08-07: Roth Says Buy The Dip In This Biotech

Financial news for BLUE dated on 2015-08-07: Roth Capital's Chattopadhyay Sees ~6% Decline in bluebird bio Shares as Offering an Attractive Entry Point; Buy Rating, \$192 Target Maintained

Financial news for BLUE dated on 2015-08-06: bluebird Bio Reports Q2 Loss \$1.57 Vs Est Loss \$0.79, Sales \$4.940M Vs Est \$8.61M

Financial news for BLUE dated on 2015-07-13: Roth Capital: Buy The Dips In Bluebird Bio

Financial news for BLUE dated on 2015-07-07: Baillie Gifford Reports 10.34% Passive Stake in Bluebird Bio as of June 30

Financial news for BLUE dated on 2015-06-24: Kite Pharma CEO: 'We Are Offering The Next Generation Immunotherapy'

Financial news for BLUE dated on 2015-06-24: Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting

Financial news for BLUE dated on 2015-06-24: bluebird bio Prices ~2.941M Share Offering @\$170.00/Share

Financial news for BLUE dated on 2015-06-23: UPDATE: Hearing 2.3M Share Offering in bluebird bio

Financial news for BLUE dated on 2015-06-23: bluebird bio Announces \$400M Offering

Financial news for BLUE dated on 2015-06-22: Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers



Financial news for BLUE dated on 2015-06-15: Bluebird Bio's Positive LentiGlobin Data: Wall Street Responds

Financial news for BLUE dated on 2015-06-15: BMO Capital Raises Target on bluebird bio from \$200 to \$239.00

Financial news for BLUE dated on 2015-06-15: Morning Market Gainers

Financial news for BLUE dated on 2015-06-15: UPDATE: Cowen Analyst on bluebird bio 'Optimistic Lenti-D, LentiGlobin Will Represent Meaningful Advances in Areas of High Unmet Need'

Financial news for BLUE dated on 2015-06-15: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2015-06-15: Cowen On Bluebird Bio Says 'we gain some reassurance from teh favorable efficacy and saftey updates on BB305'

Financial news for BLUE dated on 2015-06-15: Suntrust Maintains Buy on bluebird bio, Raises PT to \$230.00

Financial news for BLUE dated on 2015-06-15: Philip Gregory, D. Phil., Joins bluebird bio as Chief Scientific Officer

Financial news for BLUE dated on 2015-06-15: JP Morgan Maintains Overweight on bluebird bio, Raises PT to \$244.00

Financial news for BLUE dated on 2015-06-13: bluebird bio Presents New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA

Financial news for BLUE dated on 2015-06-10: Bluebird Bio Shares Under Pressure As Wedbush Warns Of Pediatric Study Delay

Financial news for BLUE dated on 2015-06-10: bluebird bio Shares Down 2.5% Premarket as Wedbush Note Highlighting NIH Advisory Panel Has Recommended Delaying Pediatric Study Initiation, But Says Does Not Impact FDA

Financial news for BLUE dated on 2015-06-10: Benzinga's Top #PreMarket Losers

Financial news for BLUE dated on 2015-06-05: What Does The Russell Reconstitution Mean For You?

Financial news for BLUE dated on 2015-06-05: Jim Cramer Shares His Thoughts On L Brands, Revance Therapeutics And bluebird bio

Financial news for BLUE dated on 2015-06-04: Analysts Weigh In On Amended Bluebird Bio/Celgene Deal

Financial news for BLUE dated on 2015-06-03: 8-K from bluebird bio on Celgene Deal Shows Co. 'will be eligible to receive up to \$10.0 million in clinical milestone payments, up to \$117.0 million in regulatory milestone payments and up to \$78.0 million in commercial milestone payments.'

Financial news for BLUE dated on 2015-06-03: Celgene, bluebird bio To Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA

Financial news for BLUE dated on 2015-05-28: BMO Capital: Five Prime Therapeutics Still A Buy, Worth \$31/Share Now

Financial news for BLUE dated on 2015-05-27: Morning Market Gainers

Financial news for BLUE dated on 2015-05-27: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2015-05-26: Five Prime Therapeutics Shares Rise 17% After-Hours Following Announcement of Deal With Bluebird Bio

Financial news for BLUE dated on 2015-05-26: bluebird bio, Five Prime Therapeutics Enter Exclusive License Agreement For Novel Antibodies To Develop Chimeric Antigen Receptor T Cell Therapy

Financial news for BLUE dated on 2015-05-26: Bluebird Bio Now Worth \$213/Share, Piper Jaffray Says

Financial news for BLUE dated on 2015-05-21: BlueBird Bio: Another Biogen Rout In The Making?

Financial news for BLUE dated on 2015-05-21: Morning Market Gainers

Financial news for BLUE dated on 2015-05-21: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2015-05-21: bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association

Financial news for BLUE dated on 2015-05-20: Wedbush Sees More News On Bluebird Bio Coming Thursday

Financial news for BLUE dated on 2015-05-19: BlueBird Bio Drug Might Get Accelerated OK In U.S., Europe

Financial news for BLUE dated on 2015-05-19: BlueBird Bio Soars Off Potential Drug Approval

Financial news for BLUE dated on 2015-05-19: JP Morgan Reiterates On Bluebird Bio, Says It's 'Still Streaking'

Financial news for BLUE dated on 2015-05-19: bluebird bio Meets With EU, US Regulatory Authorities to Discuss Potential Approval Pathways for LentiGlobin BB305

Financial news for BLUE dated on 2015-05-11: SunTrust: Bluebird Bio Might Fly On Sickle Cell Results

Financial news for BLUE dated on 2015-05-06: bluebird bio Reports Q1 Loss of \$0.76/Share vs Loss of \$0.61/Share Est.

Financial news for BLUE dated on 2015-04-30: Biogen Or Bluebird: Which Will Lead In SCD?

Financial news for BLUE dated on 2015-04-29: Piper Jaffray Maintains Overweight on bluebird bio, Raises PT to \$186.00

Financial news for BLUE dated on 2015-04-27: Adam Feuerstein @adamfeuerstein Tweet: From last night --> Gene Therapy Stocks on Watch Following Failure of \$CLDN Heart Failure Trial thestreet.com/story/13126476... \$BLUE \$QURE \$ONCE

Financial news for BLUE dated on 2015-04-22: BMO Capital Initiates Coverage on bluebird bio at Outperform, Announces \$160.00 PT

Financial news for BLUE dated on 2015-04-22: Maxim Is Going Long Bluebird Bio

Financial news for BLUE dated on 2015-04-17: Expert: Bluebird Bio Is 'One Of The Better Stories In Biotech'

Financial news for BLUE dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for BLUE dated on 2015-02-26: Bluebird Bio: Here's Why Wedbush Is Bullish

Financial news for BLUE dated on 2015-02-26: These Analysts See Upside At Continental Resources

Financial news for BLUE dated on 2015-02-25: Bluebird Bio Ticks Down On Wider Loss

Financial news for BLUE dated on 2015-02-25: bluebird bio Reports Q4 EPS -\$0.67 Vs Est -\$0.57, Sales \$6.39M Vs Est \$6.18M

Financial news for BLUE dated on 2015-02-03: Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

Financial news for BLUE dated on 2015-02-02: Mid-Day Market Update: U.S. Stocks Turn Higher; Tenneco Shares Rise On Upbeat Earnings

Financial news for BLUE dated on 2015-02-02: Mid-Morning Market Update: Markets Tumble; Exxon Mobil Profit Beats Views

Financial news for BLUE dated on 2015-02-02: Morning Market Gainers

Financial news for BLUE dated on 2015-02-02: Bluebird Bio Surges Following FDA Decision

Financial news for BLUE dated on 2015-02-02: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2015-02-02: Bluebird Bio Shares Rise 10% Premarket Following Announcement of FDA Breakthrough Therapy Designation for LentiGlobin

Financial news for BLUE dated on 2015-02-02: UPDATE: Bluebird Bio Announces FDA Breakthrough Therapy Designation for LentiGlobin

Financial news for BLUE dated on 2015-02-02: Adam Feuerstein @adamfeuerstein Tweet: \$BLUE receives FDA breakthrough therapy designation for Lentiglobin in beta thalassemia.

Financial news for BLUE dated on 2015-01-29: bluebird bio Announces Transition of Chief Scientific Officer Mitchell H. Finer, Ph.D.

Financial news for BLUE dated on 2015-01-29: bluebird bio Names Mitchell Finer Chief Scientific Officer

Financial news for BLUE dated on 2015-01-21: UPDATE: BlueBird Bio Shares Spike Higher; Hearing Wedbush Raises PT from \$94 to \$146

Financial news for BLUE dated on 2015-01-21: BlueBird Bio Spikes Higher

Financial news for BLUE dated on 2015-01-20: Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year

Financial news for BLUE dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for BLUE dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for BLUE dated on 2015-01-12: Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Financial news for BLUE dated on 2014-12-29: The Top 5 Biotech Gainers Of 2014

Financial news for BLUE dated on 2014-12-29: Roth Capital Maintains Buy on bluebird bio, Raises PT to \$120.00

Financial news for BLUE dated on 2014-12-15: bluebird bio Prices 2.65M Share Offering @\$85.00/Share

Financial news for BLUE dated on 2014-12-10: UPDATE: Wedbush Reiterates On bluebird bio On Updated Data

Financial news for BLUE dated on 2014-12-09: Mid-Morning Market Update: Markets Open Lower; AutoZone Posts Upbeat Results

Financial news for BLUE dated on 2014-12-09: Benzinga's Volume Movers

Financial news for BLUE dated on 2014-12-09: Stocks Hitting 52-Week Highs

Financial news for BLUE dated on 2014-12-09: Morning Market Movers

Financial news for BLUE dated on 2014-12-09: bluebird bio Inc Shares Up Sharply Following Positive Drug Data

Financial news for BLUE dated on 2014-12-09: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2014-12-09: UPDATE: Bluebird Bio Shares Rise 61% Premarket on Positive Lentiglobin Bb305 Results

Financial news for BLUE dated on 2014-12-09: Wedbush Reiterates Outperform on bluebird bio, Raises PT to \$94.00

Financial news for BLUE dated on 2014-12-08: UPDATE: Bluebird Bio Shares Now Up 56% After-Hours on Positive Lentiglobin Bb305 Data

Financial news for BLUE dated on 2014-12-08: UPDATE: Bluebird Bio Shares Now Up 35% After-Hours on Positive Lentiglobin Bb305 Data

Financial news for BLUE dated on 2014-12-08: bluebird bio Reports First Four Patients with b-Thalassemia Major Treated with LentiGlobin are Transfusion-Free

Financial news for BLUE dated on 2014-12-08: Bluebird Bio Shares Rise 25% After-Hours on Positive Data from Eight Subjects Treated With Lentiglobin Bb305

Financial news for BLUE dated on 2014-12-02: Ian Estepan @ianestepan Tweet: \$BLUE sounds quite bullish at Piper - they obviously know the data at ASH - people will be upset if the data underwhelms...

Financial news for BLUE dated on 2014-11-10: James M. DeTore Joins Bluebird Bio As CFO

Financial news for BLUE dated on 2014-10-03: Bluebird Bio Ceo Leschly Sells 8,000

Shares @\$34.55/Share -Form 4

Financial news for BLUE dated on 2014-09-22: Roth Capital Initiates Coverage on bluebird bio at Buy, Announces \$50.00 PT

Financial news for BLUE dated on 2014-09-16: Adam Feuerstein @adamfeuerstein Tweet: \$BLUE spox to me: "We're dosing [sickle cell patients] by end of year. We'll have clinically meaningful data in 2015."

Financial news for BLUE dated on 2014-09-04: SunTrust Robinson Humphrey Initiates Coverage on bluebird bio at Buy, Announces \$57.00 PT

Financial news for BLUE dated on 2014-09-03: Top 5 Performing Biotech Stocks Of 2014

Financial news for BLUE dated on 2014-08-12: bluebird bio Reports Q2 EPS of \$(0.06) vs \$(0.45) Est; Revenue of \$6.30M vs \$6.15M Est

Financial news for BLUE dated on 2014-07-28: 2 Biotech Stocks With Massive Increases In Short Interest

Financial news for BLUE dated on 2014-07-17: Bluebird Bio Shares Move Higher; May be Attributed to Positive Street.com Article

Financial news for BLUE dated on 2014-07-08: Bluebird Prices 3M Share Offering at \$34/Share

Financial news for BLUE dated on 2014-07-07: bluebird bio Announces Proposed Offering of \$100M in Shares

Financial news for BLUE dated on 2014-07-02: Filing from Bluebird Bio Shows Registration for Automatic Mixed Securities Shelf

Financial news for BLUE dated on 2014-06-30: Bluebird Bio Announces Acquisition of Precision Genome Engineering For ~408k Shares of Stock and Paid or Assumed \$4.9M Of Liabilities

Financial news for BLUE dated on 2014-06-20: Adam Feuerstein Likes Zafgen, Bluebird Bio

Financial news for BLUE dated on 2014-06-16: Mid-Afternoon Market Update: US Stocks Reverse Earlier Loses; Fusion-io Shares Jump On SanDisk Buyout

Financial news for BLUE dated on 2014-06-16: Mid-Day Market Movers For Monday, June 16, 2014

Financial news for BLUE dated on 2014-06-16: Mid-Day Market Update: US Stocks Turn Red; Fusion-IO Shares Jump On SanDisk Buyout

Financial news for BLUE dated on 2014-06-16: Benzinga's Volume Movers

Financial news for BLUE dated on 2014-06-16: Mid-Morning Market Update: Markets Mostly Higher; Medtronic To Acquire Covidien For \$42.9B

Financial news for BLUE dated on 2014-06-16: Stocks Hitting 52-Week Highs

Financial news for BLUE dated on 2014-06-16: Morning Market Movers

Financial news for BLUE dated on 2014-06-16: Benzinga's Top #PreMarket Gainers

Financial news for BLUE dated on 2014-06-16: bluebird bio Shares Rise 53% in Premarket, Following Presentation of Positive Data on LentiGlobin BB305 at EHA

Financial news for BLUE dated on 2014-06-14: bluebird bio Presents Positive Data on LentiGlobin BB305 at EHA

Financial news for BLUE dated on 2014-05-09: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS

Financial news for BLUE dated on 2014-04-01: 5 Healthcare Stocks With The Highest EPS

Financial news for BLUE dated on 2014-03-05: bluebird bio Reports FY EPS of \$(2.02) vs \$(1.52) Est; Revenue of \$20.20M vs \$20.18M Est

Financial news for BLUE dated on 2013-12-02: Bluebird Bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Beta-Thalassemia, Sickle Cell Anemia Study

Financial news for BLUE dated on 2013-11-18: Stocks Hitting 52-Week Lows

Financial news for BLUE dated on 2013-10-09: Stocks Hitting 52-Week Lows

Financial news for BLUE dated on 2013-08-14: bluebird bio Reports Q2 EPS of \$(2.13) Which May Not Compare \$(0.35) Est; Revenue of \$6.30M Which May Not Compare \$4.48M Est

Financial news for BLUE dated on 2013-07-30: Cowen & Company Initiates Coverage on bluebird bio at Outperform, Announces \$44.00 PT

Financial news for BLUE dated on 2013-07-15: Bluebird Initiated at Wedbush with Outperform, \$40 PT

Financial news for BLUE dated on 2013-07-15: UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products

Financial news for BLUE dated on 2013-07-15: UPDATE: Canaccord Genuity Initiates bluebird bio at Buy on Strong Gene Therapy Platform

Financial news for BLUE dated on 2013-07-15: UPDATE: Bank of America Initiates bluebird bio at Buy on Transformational Potential

Financial news for BLUE dated on 2013-07-15: Benzinga's Top Initiations

Financial news for BLUE dated on 2013-07-15: JP Morgan Initiates Coverage on bluebird bio at Overweight, Announces \$44.00 PT

Financial news for BLUE dated on 2013-07-15: Canaccord Genuity Initiates Coverage on bluebird bio at Buy, Announces \$45.00 PT

Financial news for BLUE dated on 2013-07-15: Bank of America Initiates Coverage on bluebird bio at Buy, Announces \$42.00 PO

Financial news for BLUE dated on 2013-06-28: Stocks Hitting 52-Week Lows

Financial news for BLUE dated on 2013-06-24: bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

Financial news for BLUE dated on 2013-06-19: Afternoon Market Gainers

Financial news for BLUE dated on 2013-06-19: Shares of bluebird bio Open for Trade at \$25.50/Share, Priced at \$17

Financial news for BLUE dated on 2013-06-19: bluebird bio IPO to Open This Morning, Priced ~5.94M Shares at \$17/Share, Initial Range Was \$14-16